Regeneron Pharmaceuticals (REGN) Current Deferred Revenue (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Current Deferred Revenue of $684.8 million for Q2 2026, up 42.1% year-over-year from $481.9 million in Q2 2025, and up 7.64% quarter-over-quarter from $636.2 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Current Deferred Revenue (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Current Deferred Revenue history runs 18 years deep, the most recent figure standing at $684.8 million for Q2 2026.
- In Q2 2026, Current Deferred Revenue rose 42.1% year-over-year to $684.8 million; the TTM figure through Jun 2026 stood at $684.8 million (up 42.1% YoY), while the FY2025 annual figure was $553.0 million, down 11.9% from the prior year.
- Current Deferred Revenue for Q2 2026 stood at $684.8 million, up from $636.2 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $684.8 million in Q2 2026, with the low at $381.1 million in Q2 2023.
- The 5-year median for Current Deferred Revenue is $546.4 million (2022), against an average of $535.8 million.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue tumbled 32.7% in 2023, then jumped 53.77% in 2024.
- Regeneron Pharmaceuticals' Current Deferred Revenue stood at $477.9 million in 2022, then declined by 3.98% to $458.9 million in 2023, then jumped by 36.78% to $627.7 million in 2024, then declined by 11.9% to $553.0 million in 2025, then grew by 23.83% to $684.8 million in 2026.
- Business Quant data shows REGN's Current Deferred Revenue at $684.8 million in Q2 2026, $636.2 million in Q1 2026, and $553.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 684.80 Mn |
| Mar 31, 2026 | 636.20 Mn |
| Dec 31, 2025 | 553.00 Mn |
| Sep 30, 2025 | 545.60 Mn |
| Jun 30, 2025 | 481.90 Mn |
| Mar 31, 2025 | 619.30 Mn |
| Dec 31, 2024 | 627.70 Mn |
| Sep 30, 2024 | 627.20 Mn |
| Jun 30, 2024 | 586.00 Mn |
| Mar 31, 2024 | 516.70 Mn |
| Dec 31, 2023 | 458.90 Mn |
| Sep 30, 2023 | 417.30 Mn |
| Jun 30, 2023 | 381.10 Mn |
| Mar 31, 2023 | 426.30 Mn |
| Dec 31, 2022 | 477.90 Mn |
| Sep 30, 2022 | 547.20 Mn |
| Jun 30, 2022 | 566.30 Mn |
| Mar 31, 2022 | 491.30 Mn |
| Dec 31, 2021 | 442.00 Mn |
| Sep 30, 2021 | 507.80 Mn |